Monte Middleton, APRN
Psychiatric/Mental Health · Columbus, NENPI 1669796892
Payments from drug & device makers
Across 154 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$485
- Neurocrine Biosciences, Inc.$374
- Teva Pharmaceuticals USA, Inc.$315
- Otsuka America Pharmaceutical, Inc.$315
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$303
- Johnson & Johnson$262
- plus $858 from 9 others
What the payments were for
- Food & beverage$2,78696%
- Education$1264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $485 |
| Neurocrine Biosciences, Inc. | 14 | $374 |
| Teva Pharmaceuticals USA, Inc. | 11 | $315 |
| Otsuka America Pharmaceutical, Inc. | 20 | $315 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $303 |
| Johnson & Johnson | 11 | $262 |
| Vanda Pharmaceuticals Inc. | 10 | $220 |
| Alkermes, Inc. | 7 | $149 |
| E.r. Squibb & Sons, L.L.C. | 6 | $117 |
| Supernus Pharmaceuticals, Inc. | 4 | $98 |
| Indivior Inc. | 4 | $77 |
| Corium, LLC | 2 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $44 |
How this compares
$2,912 in reported general payments places this provider in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 123 | $354,108 |
| IngrezzaValbenazine Tosylate | 27 | $216,683 |
| LybalviOlanzapine/Samidorphan Malate | 141 | $209,517 |
| VraylarCariprazine Hcl | 121 | $167,395 |
| RexultiBrexpiprazole | 70 | $113,259 |
| Risperdal ConstaRisperidone Microspheres | 56 | $110,300 |
| CaplytaLumateperone Tosylate | 28 | $49,869 |
| BelsomraSuvorexant | 60 | $26,421 |
| Paliperidone ErPaliperidone | 136 | $17,961 |
| Clozapine | 274 | $15,670 |
| Lurasidone Hcl | 88 | $14,584 |
| Vilazodone Hcl | 175 | $14,109 |
| VyvanseLisdexamfetamine Dimesylate | 35 | $13,724 |
| FetzimaLevomilnacipran Hcl | 25 | $12,073 |
| Aripiprazole | 332 | $6,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Risperdal | $262 | $469,520200 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $374 | $216,68327 claims |
| Alkermes, Inc.Lybalvi | $149 | $209,517141 claims |
| AbbVieVraylar, Fetzima | $485 | $179,468146 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $315 | $113,25970 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $303 | $49,86928 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $47 | $13,72435 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $53 | $6,03212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Columbus
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Suzanne GreggHastings$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.